Investigation into death of a woman vaccinated with AstraZeneca in Tenerife
The Canaries Health authorities are investigating the death of a woman under 50 years of age in Tenerife, who has died several days after receiving her first dose of the AstraZeneca vaccine. She received vaccination as a non-frontline essential worker for a charity (NGO) on the island, and had several health conditions that required medication and obesity.
The woman claimed to have had intense headaches days after receiving the vaccine, and was admitted to hospital. The case is being handled with prudence and caution, since authorities are waiting to know the results of the autopsy of the deceased, whose samples are also being studied in Madrid.
According to sources close to the Ministry of Health, a very special autopsy profile that takes up to three weeks must be done, due to the study of the venous sinuses, so samples must also be sent to the mainland. Once the study is finished, the conclusions will be sent to the international authorities and will be added to the rest of the investigations that are being carried out.
The Health Authorities ensure that there is no need to generate any type of alarm, as already in Spain two deaths have been ruled out for being caused by the effects of the AstraZeneca vaccine. First, was the death of a teacher from Marbella after receiving vaccination, but it was ruled out that the brain aneurysm she suffered was related to it, and the sudden death of a woman in Asturias who was inoculated with the first dose a week before death was not caused by an adverse reaction to the vaccine, according to the National Institute of Toxicology. In neither case were thrombi seen.
On the other hand, the admission into hospital of another 55-year-old woman in Asturias yesterday diagnosed with a cerebral venous sinus thrombosis was registered, after receiving the dose of AstraZeneca days before.
Vaccination is voluntary in Spain, but you cannot choose which vaccine you are inoculated with from the four that are currently authorized by the European Medicines Agency, i.e. Pfizer, Modena, AstraZeneca and Janssen. If you refuse to be vaccinated when it is your turn, you could re-engage when everyone else has been vaccinated, and when there is availability and with the same type of vaccine that was your turn at the beginning.
The EMA continues to insist that there is no scientific evidence linking the Astrazeneca vaccine with cases of thrombosis, and stressed that its benefits are greater than the risks it entails.
7 DEATHS AND 30 CASES OUT OF 18 MILLION:
The proportion of adverse reactions from administered vaccines is very small. The United Kingdom recognized 7 deaths and 30 cases of rare blood clots a few days ago among the more than 18.1 million vaccinated in the country at the end of March. Their regulatory agency explained that the risks associated with these clots "are very small" and that the population must continue to be vaccinated. Of the 30 cases, 22 correspond to venous cerebral thrombi and the remaining to problems related to blood clotting, with low platelets.
Other articles that may interest you...
A group of German researchers discovered the link between reports of rare side effects and platelets. The very unusual combination of symptoms after vaccination resembles a rare side effect of heparin called HIT. There is a surprising combination of thrombocytopenia (low platelets) and unusual clotting in a group of patients who had developed thrombosis between 4 and 16 days after receiving the vaccine. Seven of them suffered cerebral venous thrombosis and four died.
By alerting doctors to this complication, and it is recognized early, it can be treated with immunoglobulins (nonspecific antibodies from blood donors) that help slow platelet activation. Heparin-free anticoagulants can help dissolve clots, so this Vaccine-Induced Immune Prothrombotic Thrombocytopenia Syndrome (VIPIT) should be treated similarly to HIT.
Finally, as prevention and fearing a new link with the rare blood clots that cause deaths, Germany suspended vaccination with AstraZeneca in those over 60 years of age, while Canada suspended its administration in those over 55 years of age. The Netherlands has completely suspended its use.
Undoubtedly, this lack of homogeneity in the regulation generates uncertainty among the population due to the different recommendations. AstraZeneca vaccines are being administered in 80 countries and in only one case per million vaccinated are these strange events occurring.